Lutris Pharma to Present Updated Data from Its Phase 2 Trial of LUT014 Gel for the Treatment of Patients With EGFRI-Induced Acneiform Rash at the EADV Congress

Phase 2LUT014 GelNeutral

AI Analysis

Summary

Lutris Pharma announced it will present updated Phase 2 trial data for LUT014 Gel, a treatment for EGFRI-induced acneiform rash in cancer patients, at the EADV Congress.

Clinical Trial Data

Phase

Phase 2

Outcome Details

Updated data presentation at EADV Congress

Importance:5/10

Sentiment:

0.20

Phase 2 datadermatological toxicitycancer therapyconference presentationLUT014

Read the original article

Published by PR Newswire Pharma on September 16, 2026 11:03 AM

Read Original